The stock of Chromadex Corp (CDXC) has seen a -6.38% decrease in the past week, with a -10.20% drop in the past month, and a 131.58% flourish in the past quarter. The volatility ratio for the week is 7.07%, and the volatility levels for the past 30 days are at 8.57% for CDXC. The simple moving average for the past 20 days is -4.24% for CDXC’s stock, with a 85.47% simple moving average for the past 200 days.
Is It Worth Investing in Chromadex Corp (NASDAQ: CDXC) Right Now?
The stock has a 36-month beta value of 1.97. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CDXC is 44.80M, and at present, short sellers hold a 3.31% of that float. On May 10, 2024, the average trading volume of CDXC was 341.76K shares.
CDXC) stock’s latest price update
The stock of Chromadex Corp (NASDAQ: CDXC) has decreased by -8.09 when compared to last closing price of 3.83.Despite this, the company has seen a loss of -6.38% in its stock price over the last five trading days. Business Wire reported 2024-04-24 that LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference C.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at 10.61% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.30% of loss for the given period.
Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 7.07%, as shares sank -13.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +104.65% upper at present.
During the last 5 trading sessions, CDXC fell by -6.38%, which changed the moving average for the period of 200-days by +112.05% in comparison to the 20-day moving average, which settled at $3.65. In addition, Chromadex Corp saw 146.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Gerber Brianna, who purchase 5,000 shares at the price of $1.41 back on Dec 01 ’23. After this action, Gerber Brianna now owns 27,436 shares of Chromadex Corp, valued at $7,050 using the latest closing price.
Jaksch Frank L Jr, the Director of Chromadex Corp, purchase 7,000 shares at $1.69 during a trade that took place back on Jun 12 ’23, which means that Jaksch Frank L Jr is holding 231,339 shares at $11,830 based on the most recent closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- -0.04 for the present operating margin
- 0.55 for the gross margin
The net margin for Chromadex Corp stands at -0.04. The total capital return value is set at -0.11. Equity return is now at value -12.39, with -6.54 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 1.41. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 60.03.
Currently, EBITDA for the company is -0.19 million with net debt to EBITDA at 9.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.63. The receivables turnover for the company is 13.91for trailing twelve months and the total asset turnover is 1.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.52.
Conclusion
To sum up, Chromadex Corp (CDXC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
